kyoto.jpeg

kyoto

kyotovisitorshost.jpeg

kyotovisitorshost

General information

Announcements(0)

Overview

Pre-registration

Abstract Submission (Oral/Poster Presentation)

Guidelines for Writing Abstracts (Oral/Poster Pres

Program

Sessions

Search presentations

pharm140_e.png

icon_20251203154432448.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

A password that applicants have been notified of is required to view abstracts. If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts. We will reply after confirming that you were a participant. Thank you for your understanding.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Profile management

Announcements

Bookmark

Download PDF for print

Timetable

Introduction to “neobiologics”, a new modality of protein drugs developed by using "LassoGraft Technology"

Biopharmaceuticals such as therapeutic antibodies are expected to show efficacy not achieved by conventional small molecule drugs, and have continued to evolve as drugs that meet unmet medical needs. Japan had been behind in the development of therapeutic antibodies, however, new trends are emerging in product development, training for manufacturing and quality control, and research in personalized medicinal treatment, because the expansion of products and their indications became them more important in clinical field. Recent topics include the increase in the products originated in Japan, and establishment of the Biologics Research Training Center. With the diversification of products, pioneering results on personalized medicine, which will be important in this field, are being obtained. In addition, standardization of fundamental technologies is also progressing in regulatory science research that links advanced technologies with drug development and implementation in post-approval phase. In this symposium, development of innovative biopharmaceuticals, education of human resource for manufacturing and quality control, regulatory science, and clinical research for personalized medicine are presented.Then the latest trends related to development and clinical implementation of biopharnaceuticals that can be expected to contribute from Japan to other countries including Asia in a new era will be discussed.

"Drug discovery" and "health care" of biopharnaceuticals: Considerations in future development and clinical usage of biopharmaceuticals

The 140th Annual Meeting of the Pharmaceutical Society of Japan (Kyoto)

Presentation Information

[S19-1]Introduction to “neobiologics”, a new modality of protein drugs developed by using "LassoGraft Technology"

Password required to view